MAP2K7 and acute myeloid leukemia: AML cell lines MOLM-13 and OCI-AML3, which were susceptible to trametinib, had elevated MEK levels, while OCI-AML2 and MOLM-16, both unsusceptible to trametinib, had very low MEK levels.